Numerical chromosomal changes in DNA hypodiploid solid tumors: Restricted loss and gain of certain chromosomes

被引:0
|
作者
El-Naggar, AK
Dinh, M
Tucker, SL
Swanson, D
Steck, K
Vielh, P
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Surg, Houston, TX 77030 USA
[4] Inst Curie, Sect Cytopathol, Paris, France
来源
CYTOMETRY | 1999年 / 37卷 / 02期
关键词
DNA hypodiploidy; solid tumors; in situ hybridization; chromosomal abnormalities; flow cytometry;
D O I
10.1002/(SICI)1097-0320(19991001)37:2<107::AID-CYTO3>3.0.CO;2-O
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: DNA hypodiploidy is a unique and rare finding associated with aggressive behavior in solid tumors. Identifying the chromosomal changes underlying this feature may provide important information on the development and progression of these neoplasms. Methods: Fluorescence in situ hybridization analysis using oc-satellite probes for nine autosomes and the two sex chromosomes was performed on interphase cells from 27 solid tumors which had been shown to be DNA hypodiploid by flow cytometry. The chromosomal abnormalities were correlated with the DNA index and tumor subtypes. Results: The data show mutually exclusive loss of certain chromosomes and compensatory gain of other chromosomes in different tumors. The net loss was slightly more than the net gain for the chromosomes tested. Polysomy of chromosome 7 and monosomy of chromosomes 17, X and loss Y were found in most tumors. Significant differential loss of chromosomes 6,10, and 12 among DNA hypodiploid breast, kidney and lung carcinomas was noted. Conclusions: Our study shows (i) gain of chromosome 7 and loss chromosome 17 in most DNA hypodiploid tumors, (ii) specific chromosomal loss was noted in breast and renal cell carcinomas, and (iii) that different mechanisms for DNA hypodiploid and hyperdiploid development may exist. Cytometry 37:107-112, 1999 (C) 1999 Wiley-Liss, Inc.
引用
收藏
页码:107 / 112
页数:6
相关论文
共 19 条
  • [11] Changes in circulating tumor DNA (ctDNA) and outcomes in solid tumors treated with immune checkpoint inhibitors (ICIs)
    Al-Showbaki, Laith
    Iafolla, Marco
    Tamimi, Faris
    Molto, Consolacion
    Mittal, Abhenil
    Cescon, David W.
    Amir, Eitan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [12] OPTIMIZING COMPARATIVE GENOMIC HYBRIDIZATION FOR ANALYSIS OF DNA-SEQUENCE COPY NUMBER CHANGES IN SOLID TUMORS
    KALLIONIEMI, OP
    KALLIONIEMI, A
    PIPER, J
    ISOLA, J
    WALDMAN, FM
    GRAY, JW
    PINKEL, D
    GENES CHROMOSOMES & CANCER, 1994, 10 (04): : 231 - 243
  • [13] Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review
    Al-Showbaki, Laith
    Wilson, Brooke
    Tamimi, Faris
    Molto, Consolacion
    Mittal, Abhenil
    Cescon, David W.
    Amir, Eitan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (02)
  • [15] Alteration of numerical chromosomal aberrations during progression of colorectal tumors revealed by a combined fluorescence in situ hybridization and DNA ploidy analysis of intratumoral heterogeneity
    Katsura, K
    Sugihara, H
    Nakai, S
    Fujita, S
    CANCER GENETICS AND CYTOGENETICS, 1996, 90 (02) : 146 - 153
  • [16] DNA deformability changes of single base pair mutants within CDE binding sites in S-Cerevisiae centromere DNA correlate with measured chromosomal loss rates and CDE binding site symmetries
    Hennemuth, B
    Marx, KA
    BMC MOLECULAR BIOLOGY, 2006, 7
  • [17] DNA deformability energetic changes associated with single base pair mutants of CDE binding sites within S-cerevisiae centromere DNAs correlate with measured chromosomal loss rates
    不详
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2005, 22 (06): : 786 - 787
  • [18] Whole genome SNP arrays for best practice for detection of diagnostic, prognostic and therapy related copy number changes and copy neutral-loss of heterozygosity across solid tumors and hematologic malignancies.
    Lennon, Patrick Alan
    Raca, Gordana
    Fang, Min
    Wolff, Daynna
    Li, Marilyn M.
    Iqbal, Anwar M.
    Levy, Brynn
    Schwartz, Stuart
    Dubuc, Adrian M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [19] Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors.
    Spira, Alexander I.
    Papadopoulos, Kyriakos P.
    Kim, Dae Won
    Parikh, Aparna Raj
    Barve, Minal A.
    Powderly, John D.
    Starodub, Alexander
    Strickler, John H.
    Li, Bob T.
    Oberstein, Paul Eliezer
    Hassan, Faisal
    Yang, Michelle
    Mccleland, Mark
    Lally, Satwant
    Lin, Wei
    Sohoni, Sophia
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 724 - 724